3billion, Inc.

KOSDAQ:A394800 Stock Report

Market Cap: ₩323.6b

3billion Past Earnings Performance

Past criteria checks 0/6

3billion has been growing earnings at an average annual rate of 54.9%, while the Biotechs industry saw earnings growing at 16.9% annually. Revenues have been growing at an average rate of 44.8% per year.

Key information

54.86%

Earnings growth rate

26.93%

EPS growth rate

Biotechs Industry Growth11.70%
Revenue growth rate44.76%
Return on equity-22.93%
Net Margin-46.22%
Last Earnings Update31 Dec 2025

Recent past performance updates

Recent updates

Analysis Article Oct 16

Companies Like 3billion (KOSDAQ:394800) Can Afford To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article Jul 10

Companies Like 3billion (KOSDAQ:394800) Can Afford To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Revenue & Expenses Breakdown

How 3billion makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

KOSDAQ:A394800 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 2511,709-5,41100
30 Sep 259,784-5,96711,7193,664
30 Jun 258,149-6,42010,5553,664
31 Mar 256,847-6,5059,1733,647
31 Dec 245,772-6,5728,2703,664
30 Sep 244,829-5,5569,363847
30 Jun 244,248-4,5668,0821,693
31 Mar 243,309-4,8626,3633,471
31 Dec 232,730-5,0926,1363,521
31 Dec 22828-3,1455,1092,993
31 Dec 21551-59,1054,4692,483
31 Dec 2025-18,4941,6752,164
31 Dec 1930-3,614959351

Quality Earnings: A394800 is currently unprofitable.

Growing Profit Margin: A394800 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: A394800 is unprofitable, but has reduced losses over the past 5 years at a rate of 54.9% per year.

Accelerating Growth: Unable to compare A394800's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: A394800 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (25.4%).


Return on Equity

High ROE: A394800 has a negative Return on Equity (-22.93%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/26 01:12
End of Day Share Price 2026/05/22 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

3billion, Inc. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
SungKyu HeoShinhan Investment Corp.